Fox Run Management L.L.C. Has $989,000 Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Fox Run Management L.L.C. grew its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 214.9% in the 2nd quarter, Holdings Channel reports. The fund owned 35,743 shares of the company’s stock after purchasing an additional 24,391 shares during the quarter. Fox Run Management L.L.C.’s holdings in Kiniksa Pharmaceuticals International were worth $989,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of KNSA. Nuveen LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at approximately $16,992,000. Acadian Asset Management LLC lifted its stake in Kiniksa Pharmaceuticals International by 170.3% in the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company’s stock valued at $22,961,000 after buying an additional 651,700 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 149.1% in the first quarter. AQR Capital Management LLC now owns 491,761 shares of the company’s stock valued at $10,922,000 after buying an additional 294,319 shares during the period. Deutsche Bank AG increased its position in shares of Kiniksa Pharmaceuticals International by 177.1% during the first quarter. Deutsche Bank AG now owns 394,522 shares of the company’s stock worth $8,762,000 after acquiring an additional 252,125 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter worth $4,663,000. Institutional investors own 53.95% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on KNSA shares. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Citigroup boosted their target price on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Finally, Wedbush reaffirmed an “outperform” rating and set a $48.00 price target (up from $44.00) on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, October 28th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $52.00.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ KNSA opened at $38.37 on Friday. The stock has a 50 day moving average price of $37.41 and a 200 day moving average price of $31.77. The stock has a market capitalization of $2.84 billion, a PE ratio of 85.27 and a beta of 0.16. Kiniksa Pharmaceuticals International, plc has a 52 week low of $17.82 and a 52 week high of $42.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The company had revenue of $180.85 million for the quarter, compared to the consensus estimate of $166.64 million. During the same quarter in the prior year, the company earned ($0.18) EPS. The company’s revenue for the quarter was up 61.2% on a year-over-year basis. As a group, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 12,368 shares of the stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $37.67, for a total value of $465,902.56. Following the completion of the sale, the chief operating officer owned 28,684 shares in the company, valued at $1,080,526.28. This trade represents a 30.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Sanj K. Patel sold 97,390 shares of the business’s stock in a transaction dated Wednesday, October 22nd. The stock was sold at an average price of $38.83, for a total transaction of $3,781,653.70. Following the transaction, the chief executive officer owned 111,794 shares in the company, valued at $4,340,961.02. This represents a 46.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 784,112 shares of company stock valued at $28,685,561. 53.48% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.